UB Paderborn / Katalog / Suche / in CDI

1 – 11 von 11

Sortiert nach

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

Journal of clinical oncology, 2010-11, Vol.28 (31), p.4722-4729

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Journal of clinical oncology, 2010-05, Vol.28 (13), p.2137-2143

2010

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5422-5428

2008

Link zum Volltext

Verfügbarkeit prüfen

Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2005-2005

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e13526-e13526

2019

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Cytogenetic and Molecular Genetic Detection of t(8;21) and inv(16) in a Prospective Series of Adults With De Novo Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Journal of clinical oncology, 2001-05, Vol.19 (9), p.2482-2492

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e13518-e13518

2016

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy for Glioblastoma: The Devil Is in the Details Reply

Journal of clinical oncology, 2011-08, Vol.29 (22), p.3105

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e13030-e13030

2015

Link zum Volltext

Verfügbarkeit prüfen

Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3069-3069

2014

Link zum Volltext

Verfügbarkeit prüfen

Reply to M.S. Lesniak

Journal of clinical oncology, 2011-08, Vol.29 (22), p.3105-3106

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 11 von 11

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Zeitschrift / SerieBulletin Of The American Library Association

PublikationsformBerichte

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11)
Mit Volltextzugriff
(11)

Publikationsform

Artikel
(11)

Sprache

Englisch
(11)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(5)
Oncology
(5)
Science & Technology
(5)
Biological And Medical Sciences
(4)
Female
(4)
Humans
(4)
Male
(4)
Medical Sciences
(4)
Middle Aged
(4)
Adult
(3)
Disease-Free Survival
(3)
Prospective Studies
(3)
Tumors
(3)
Aged
(2)
Antibodies, Monoclonal - Administration & Dosage
(2)
Antibodies, Monoclonal, Humanized
(2)
Bevacizumab
(2)
Carcinoma, Renal Cell - Drug Therapy
(2)
Carcinoma, Renal Cell - Secondary
(2)
Drug Administration Schedule
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma

Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma

Comparison of Cytogenetic and Molecular Genetic Detection of t(8;21) and inv(16) in a Prospective Series of Adults With De Novo Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM)

Immunotherapy for Glioblastoma: The Devil Is in the Details Reply

Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM)

Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM)

Reply to M.S. Lesniak

Aktive Filter

Suchergebnisse filtern